Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others?

BACKGROUND alpha(2)-Macroglobulin (alpha(2)M) is a multifactorial binding protein, found in follicular fluid, that is a naturally occurring inhibitor of vascular endothelial growth factor (VEGF). The aim of this study was to determine if there is a relationship between serum VEGF levels, alpha(2)M levels and the development of OHSS in hyperstimulated subjects undergoing IVF (those with 15 or more oocytes). METHODS Venous blood was collected at the time of oocyte retrieval from subjects who yielded 15 or more oocytes. Serum samples were analysed for VEGF and alpha(2)M concentrations. RESULTS There was no statistically significant difference in serum VEGF levels at the time of oocyte retrieval between hyperstimulated subjects who did and did not subsequently develop OHSS [3.95 (3.3-4.4) versus 3.85 (3.3-4.5); P = 0.79]. By contrast, the serum level of alpha(2)M was statistically significantly higher in the group of subjects who did not develop OHSS [2.27 (1.91-2.58) versus 1.67 (1.45-1.73)]. CONCLUSIONS These results suggest that elevated alpha(2)M levels are associated with a decreased risk of developing OHSS. alpha(2)M may act by 'removing and inactivating' VEGF, with higher levels providing increased protection against the syndrome. alpha(2)M measurements may help to differentiate those for whom it is safe to proceed with embryo transfer from those for whom it is not, because of the risk of OHSS.

[1]  A. Tsafriri,et al.  Molecular aspects of mammalian ovulation. , 2009, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[2]  M. Brännström,et al.  Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[3]  R. Jaffe,et al.  Role of vascular endothelial growth factor in ovarian physiology and pathology. , 2000, Fertility and sterility.

[4]  I. Asplin,et al.  The conformation-dependent interaction of alpha 2-macroglobulin with vascular endothelial growth factor. A novel mechanism of alpha 2-macroglobulin/growth factor binding. , 2000, The Journal of biological chemistry.

[5]  Y. S. Yang,et al.  Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. , 2000, Human reproduction.

[6]  W. Jelkmann,et al.  Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. , 1999, Human reproduction.

[7]  R. Stones,et al.  Southampton, Southampton, UK , 2022 .

[8]  J. Williamson,et al.  Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. , 1999, Investigative ophthalmology & visual science.

[9]  U. Waldenström,et al.  High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study. , 1999, Human reproduction.

[10]  V. Barak,et al.  Follicular fluid levels of vascular endothelial growth factor. Are they predictive markers for ovarian hyperstimulation syndrome? , 1999, The Journal of reproductive medicine.

[11]  A. Yuzpe,et al.  Withholding gonadotropins ("coasting") to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles. , 1999, Fertility and sterility.

[12]  S. Campbell,et al.  Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. , 1999, Fertility and sterility.

[13]  E. Levin,et al.  Role of vascular endothelial cell growth factor in Ovarian Hyperstimulation Syndrome. , 1998, The Journal of clinical investigation.

[14]  M. Dhont,et al.  Prevention of severe ovarian hyperstimulation by coasting. , 1998, Fertility and sterility.

[15]  K. Kasai,et al.  Power and colour Doppler ultrasonography for the evaluation of the vasculature of the human corpus luteum. , 1998, Human reproduction.

[16]  A. Genazzani,et al.  Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. , 1998, Fertility and sterility.

[17]  S. Smith Angiogenesis, vascular endothelial growth factor and the endometrium. , 1998, Human reproduction update.

[18]  S. Campbell,et al.  Serum vascular endothelial growth factor concentrations and ovarian stromal blood flow are increased in women with polycystic ovaries. , 1998, Human reproduction.

[19]  R. Stouffer,et al.  Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. , 1997, Fertility and sterility.

[20]  A. Ferrari,et al.  Expression of vascular endothelial growth factor in human luteinizing granulosa cells and its correlation with the response to controlled ovarian hyperstimulation. , 1997, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[21]  P. Wood,et al.  Variation in Detection of VEGF in Maternal Serum by Immunoassay and the Possible Influence of Binding Proteins , 1997, Annals of clinical biochemistry.

[22]  H. Jacobs,et al.  Severe ovarian hyperstimulation syndrome: serum and ascitic fluid concentrations of vascular endothelial growth factor. , 1997, Current opinion in obstetrics & gynecology.

[23]  J. Schenker,et al.  Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[24]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[25]  Z. Ben-Rafael,et al.  The immune system in severe ovarian hyperstimulation syndrome. , 1996, Israel journal of medical sciences.

[26]  D. Redmer,et al.  Angiogenesis in the ovary. , 1996, Reviews of reproduction.

[27]  S. Berga,et al.  Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. , 1996, Fertility and sterility.

[28]  M. Breckwoldt,et al.  Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. , 1995, The Journal of clinical endocrinology and metabolism.

[29]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[30]  A. Pedram,et al.  Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome , 1995 .

[31]  D. Connolly,et al.  Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome , 1994, The Lancet.

[32]  S. Soker,et al.  Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. , 1993, The Journal of biological chemistry.

[33]  D. Brann,et al.  Characterization of the kinin system in the ovary during ovulation in the rat. , 1992, Biology of reproduction.

[34]  E. Wallach,et al.  Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. , 1992, Fertility and sterility.

[35]  J. Winer,et al.  The vascular endothelial growth factor family of polypeptides , 1991, Journal of cellular biochemistry.

[36]  T. Curry,et al.  Alpha 2-macroglobulin and tissue inhibitor of metalloproteinases: collagenase inhibitors in human preovulatory ovaries. , 1990, Endocrinology.

[37]  J. Richards,et al.  Hormonal regulation and tissue-specific localization of alpha 2-macroglobulin in rat ovarian follicles and corpora lutea. , 1989, Endocrinology.

[38]  A. Golan,et al.  Ovarian hyperstimulation syndrome: an update review. , 1989 .

[39]  S. Shapiro,et al.  Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. , 1983, Fertility and sterility.

[40]  J. Schenker,et al.  Ovarian Hyperstimulation Syndrome: A Current Survey , 1978 .

[41]  H. Kentenich,et al.  Cytokines in the follicular fluid of stimulated and non-stimulated human ovaries; is ovulation a suppressed inflammatory reaction? , 1999, Human reproduction.

[42]  W. Jelkmann,et al.  Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome. , 1998, Human reproduction.

[43]  K. James Interactions between cytokines and α2-macroglobulin , 1990 .

[44]  K. James Interactions between cytokines and alpha 2-macroglobulin. , 1990, Immunology today.